PubMed

Validity of models for predicting BRCA1 and BRCA2 mutations.

Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, Ziogas A, Weber BL, Eisen A, Malone KE, Daling JR, Hsu L, Ostrander EA, Peterson LE, Schildkraut JM, Isaacs C, Corio C, Leondaridis L, Tomlinson G, Amos CI, Strong LC, Berry DA, Weitzel JN, Sand S, Dutson D, Kerber R, Peshkin BN, Euhus DM.

Ann Intern Med. 2007 Oct 2;147(7):441-50.PMID: 17909205 [PubMed - indexed for MEDLINE]Related articlesFree article

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, Lerman C, Watson P, Lynch HT, Hilsenbeck SG, Rubinstein WS, Hughes KS, Parmigiani G.

J Clin Oncol. 2002 Jun 1;20(11):2701-12.PMID: 12039933 [PubMed - indexed for MEDLINE]Related articles

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.

Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, Shanley S, Pichert G, Izatt L, Rose S, Douglas F, Eccles D, Morrison PJ, Scott J, Zimmern RL, Easton DF, Pharoah PD.

J Med Genet. 2008 Jul;45(7):425-31. Epub 2008 Apr 15.PMID: 18413374 [PubMed - indexed for MEDLINE]Related articles

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.

Antoniou AC, Durocher F, Smith P, Simard J, Easton DF; INHERIT BRCAs program members.

Breast Cancer Res. 2006;8(1):R3. Epub 2005 Dec 12.PMID: 16417652 [PubMed - indexed for MEDLINE]Related articlesFree article

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI.

JAMA. 2005 Oct 19;294(15):1925-33.PMID: 16234499 [PubMed - indexed for MEDLINE]Related articlesFree article

BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.

Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.

Ann Oncol. 2006 Jun;17 Suppl 7:vii34-40.PMID: 16760289 [PubMed - indexed for MEDLINE]Related articlesFree article

Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.

Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, Foulkes WD, Provencher D, Tonin PN.

Clin Genet. 2006 Oct;70(4):320-9.PMID: 16965326 [PubMed - indexed for MEDLINE]Related articles

Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.

Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH.

Breast Cancer Res. 2008;10(4):R59. Epub 2008 Jul 16.PMID: 18627636 [PubMed - indexed for MEDLINE]Related articlesFree article

BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.

Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B.

J Clin Oncol. 2007 Oct 10;25(29):4635-41.PMID: 17925560 [PubMed - indexed for MEDLINE]Related articles

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.

Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G.

J Natl Cancer Inst. 2002 Jun 5;94(11):844-51.PMID: 12048272 [PubMed - indexed for MEDLINE]Related articlesFree article

Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.

Rao NY, Hu Z, Li WF, Huang J, Ma ZL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Feb;113(3):467-77. Epub 2008 Mar 16.PMID: 18343994 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. Validity of models for predicting BRCA1 and BRCA2 mutations.

[No authors listed]

Ann Intern Med. 2007 Oct 2;147(7):I38. No abstract available. PMID: 17909202 [PubMed - indexed for MEDLINE]Related articlesFree article

Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.

Armstrong K, Micco E, Carney A, Stopfer J, Putt M.

JAMA. 2005 Apr 13;293(14):1729-36.PMID: 15827311 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.

Rao NY, Hu Z, Yu JM, Li WF, Zhang B, Su FX, Wu J, Shen ZZ, Huang W, Shao ZM.

Breast Cancer Res Treat. 2009 Aug;116(3):563-70. Epub 2008 Sep 19.PMID: 18807178 [PubMed - indexed for MEDLINE]Related articles

Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.

Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group.

J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. Epub 2008 Oct 28.PMID: 18957670 [PubMed - indexed for MEDLINE]Related articlesFree article

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Parmigiani G, Berry D, Aguilar O.

Am J Hum Genet. 1998 Jan;62(1):145-58.PMID: 9443863 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE.

J Clin Oncol. 2008 Nov 20;26(33):5393-400. Epub 2008 Sep 29. Erratum in: J Clin Oncol. 2009 May 10;27(14):2415. PMID: 18824701 [PubMed - indexed for MEDLINE]Related articlesFree article

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.

Cancer. 2005 Dec 15;104(12):2807-16.PMID: 16284991 [PubMed - indexed for MEDLINE]Related articlesFree article

Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.

Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER.

BMC Cancer. 2008 May 30;8:155.PMID: 18513387 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of BRCA1 and BRCA2 mutations in a large United States sample.

Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G.

J Clin Oncol. 2006 Feb 20;24(6):863-71.PMID: 16484695 [PubMed - indexed for MEDLINE]Related articlesFree article